(MENAFN- GlobeNewsWire - Nasdaq) The AMD pipeline presents opportunities via emerging novel therapies focusing on innovative mechanisms such as gene therapy, mitochondria-targeting peptides, and complement inhibition. Key drugs in various stages of development emphasize new delivery methods and genetic approaches, offering potential advancements over existing treatments.

Dublin, Oct. 22, 2025 (GLOBE NEWSWIRE) -- The "Age-Related Macular Degeneration (AMD) - Pipeline Insight, 2025" has been added to ResearchAndMarkets's offering.

The "Age-Related Macular Degeneration (AMD) - Pipeline Insight, 2025" report offers a sweeping review of the landscape, featuring insights from over 70 companies and 75 pipeline drugs. It brings to light detailed profiles of drugs under clinical and nonclinical stages, while also assessing therapeutics by product type, trial stage, administration route, and molecule type. Detailed coverage of inactive pipeline products is also included, giving a holistic view.

Understanding Age-Related Macular Degeneration (AMD)

AMD is a chronic eye condition marked by central vision loss, largely impacting individuals over 50. The disease exists in two forms: dry (atrophic) and wet (neovascular), with the former more prevalent. Though no cure exists, treatments can slow progression and manage symptoms. Factors like aging, genetics, and lifestyle contribute to its onset.

Treatment and Diagnostics for AMD

The report details current treatments like anti-VEGF injections for wet AMD and lifestyle modifications with supplements for dry AMD. Diagnostic approaches include comprehensive eye exams, visual acuity tests, and advanced imaging techniques (e.g., OCT and fluorescein angiography) for accurate detection and progression assessment.

Pipeline Insights and Emerging Therapies

Promising innovations feature prominently in this landscape. Leading candidates include AbbVie's Surabgene Lomparvovec, a gene therapy aimed at wet AMD, showing significant reduction in the necessity for supplemental treatments. Stealth BioTherapeutics' Elamipretide targets mitochondrial enhancement, currently in a Phase III trial for dry AMD. Novartis is progressing with Iptacopan, an oral treatment in Phase II designed to prevent earlier stage disease from advancing. BenoBio's BBRP 11001, a BET protein inhibitor, is undergoing Phase I trials for wet AMD. Surrozen also emerges with the preclinical SZN 8143, a trispecific antibody targeting multiple pathways for comprehensive disease management.

Therapeutic Assessment and Research Activities

Insights into the pipeline provide a breakdown by drug phases: late-stage (Phase III), mid-stage (Phase II), early-stage (Phase I), and preclinical/discovery phases. Details on routes of administration, from intravitreal to oral delivery, and molecule types such as monoclonal antibodies and small molecules are covered. The exploration of collaborations, mergers, and acquisitions underlines the active developments in this field.

Key Companies and Products

Leading players highlighted include AbbVie, Stealth BioTherapeutics, Novartis, and Surrozen. Among key products are Surabgene Lomparvovec, Elamipretide, Iptacopan, and SZN 8143.

This report serves as a vital resource for understanding the current and future therapeutic landscape of AMD, highlighting emerging treatments and the shifting dynamics driven by collaborative efforts within the sector.

Key Topics Covered:
Introduction
Executive Summary
Age-related macular degeneration (AMD): Overview

• Causes
• Mechanism of Action
• Signs and Symptoms
• Diagnosis
• Disease Management

Pipeline Therapeutics

• Comparative Analysis

Therapeutic Assessment

• Assessment by Product Type
• Assessment by Stage and Product Type
• Assessment by Route of Administration
• Assessment by Stage and Route of Administration
• Assessment by Molecule Type
• Assessment by Stage and Molecule Type

Age-related macular degeneration (AMDD) - DelveInsight's Analytical Perspective
Late Stage Products (Phase III)

• Comparative Analysis

Surabgene Lomparvovec: AbbVie

• Product Description
• Research and Development
• Product Development Activities

Mid Stage Products (Phase II)

• Comparative Analysis

Iptacopan: Novartis Pharmaceuticals

• Product Description
• Research and Development
• Product Development Activities

Early Stage Products (Phase I)

• Comparative Analysis

BBRP 11001: BenoBio

• Product Description
• Research and Development
• Product Development Activities

Preclinical and Discovery Stage Products

• Comparative Analysis

SZN 8143: Surrozen

• Product Description
• Research and Development
• Product Development Activities

Inactive Products

• Comparative Analysis

Age-related macular degeneration (AMD) Key Companies
Age-related macular degeneration (AMD) Key Products
Age-related macular degeneration (AMDU) - Unmet Needs
Age-related macular degeneration (AMDM) - Market Drivers and Barriers
Age-related macular degeneration (AMDF) - Future Perspectives and Conclusion
Age-related macular degeneration (AMD) Analyst Views
Age-related macular degeneration (AMD) Key Companies

• AbbVie
• RemeGen
• Stealth BioTherapeutics
• Theratocular Biotek
• Novartis Pharmaceuticals
• Clearside Biomedical
• BenoBio
• Chengdu Origen Biotechnology Co., Ltd
• Surrozen
• Anida Pharma
• Belite Bio, Inc
• Luxa Biotechnology LLC

For more information about this clinical trials report visit

About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

CONTACT: CONTACT: Laura Wood,Senior Press Manager... For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900

MENAFN22102025004107003653ID1110231580